Copy Link Print Information

Abemaciclib methanesulfonate

(Synonyms: LY2835219 methanesulfonate)
123 Cited Publications
Customer Review

Based on 123 publication(s) in Google Scholar

Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective and BBB-permeable CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.

For research use only. We do not sell to patients.

  • Purity: 99.84%
  • CAS No.: 1231930-82-7
  • Formula: C28H36F2N8O3S
  • Molecular Weight:602.70
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

  • Abemaciclib methanesulfonate Chemical Structure
    Abemaciclib methanesulfonate Chemical Structure
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
  • Experimental Validation Results for Abemaciclib methanesulfonate
CAS No.: 1231930-82-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Abemaciclib methanesulfonate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocol
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Abemaciclib methanesulfonate

More
Customer Validation & Images
In Vivo Efficacy StudyWBCell Proliferation/Viability Assay
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB
  • WB

All CDK Isoforms

More
Keywords
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Abemaciclib methanesulfonate Chemical Structure
    Abemaciclib methanesulfonate Chemical Structure
    1/16
  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: NPJ Precis Oncol. 2025 Nov 21;9(1):373. [Abstract]

    Customer Validation
     MCL17-PDX mice were treated as indicated: vehicle (n = 5), abemaciclib (50 mg/kg, oral, daily; n = 5), and volasertib (5 mg/kg, intraperitoneal, weekly; n = 5). Tumor size was measured every 7 days during the treatment. Tumor volume = length x width2/2. Mice were euthanized after 21 days of treatment. Tumors were excised and weighed in comparison between each group.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 25;12(1):5112. [Abstract]

    Customer Validation
     MPF-R and TPF-R cells were treated with different concentrations of the CDK4/6 inhibitor (CDK4/6i) Palbociclib (HY-A0065), Ribociclib (HY-15777C) or Abemaciclib (HY-16297A) for 6 days. Cell growth was measured by crystal violet colorimetric assay. Growth relative to vehicle (%) is plotted against log drug concentration.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Nature. 2017 Aug 24;548(7668):471-475. [Abstract]

    Customer Validation
     Western blot of SKBR3, BT474, MDA-MB-453, and MDA-MB-361 cells treated with DMSO, GW572016, or Abemaciclib for 48 h. Western blot of MDA-MB-453 cells pretreated with DMSO or Abemaciclib (500 nM) for 0, 1, or 7 days before exposure to Staurosporine (500 nM) for 4 h.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2017 May 1;77(9):2488-2499. [Abstract]

    Customer Validation
     Treatment with PD 0332991 and Abemaciclib shows an induction of S241 P-PDK1 as early as 1 h after drug exposure without an increased in total PDK1 protein.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2017 Jan 15:124:29-42. [Abstract]

    Customer Validation
     Effect of LY2835219 on the expression of ABCB1 or ABCG2 in MDR cells. The protein level of ABCB1 and ABCG2 on MDR cells after 0, 0.1, 0.2 and 0.4 μM LY2835219 stimulation for 48h are measured by Western blot analysis, and mRNA level are measured by PCR (GAPDH as loading control).

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2017 Aug;11(8):1035-1049. [Abstract]

    Customer Validation
     Effects of CDK4/6 inhibitors on AMPK phosphorylation and apoptosis-related signals. After 24 h of drug treatment, the cells are subjected to western blot analysis. AMPK phosphorylation level is quantified by the ratio of band intensities of phospho-AMPKα vs. AMPKα.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jun 27;8(40):67422-67438. [Abstract]

    Customer Validation
     GTSE1 protein and mRNA levels in MDA-MB-157 and MDA-MB-231 cell lines treated respectively with Abemaciclib 0.5 μM for 24h. Data are presented as mean±SEM of three independent experiments.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]

    Customer Validation
     Abemaciclib causes increased PARP cleavage in RCC. In 786-O cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with SU 11248.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 27;8(56):95116-95134. [Abstract]

    Customer Validation
     Abemaciclib causes increased PARP cleavage in RCC. In Caki-1 cells Abemaciclib exposure results in increased PARP cleavage. This effect is more rapid and pronounced when Abemaciclib is combined with SU 11248.

  • 1/16

    Abemaciclib methanesulfonate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2016 Nov 15;76(22):6723-6734. [Abstract]

    Customer Validation
     The effects of the CDK inhibitor Abemaciclib, PD 0332991 and Ribocilib on Trop2 ICD cleavage. CDK inhibitors decrease Trop2 ICD abundance after the 2nd day of CDK inhibitor treatment.

  • Abemaciclib methanesulfonate